^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EPIM-001

    i
    Other names: EPIM-001, EPIM 001
    Company:
    Elpis Biopharma
    Drug class:
    PD-L1 inhibitor, IL-2Rβ partial agonist
    Related drugs:
    2years
    Discovery of EPIM-001, a tumor targeted engineered IL2 with biased IL2Rβ agonist activities (AACR 2022)
    Furthermore, in the human breast cancer cell line MDA-MB-231, EPIM-001 showed stronger tumor growth inhibition compared to Keytruda. EPIM-001 is a promising immune modulating drug candidate that selectively activates CD8+ T cells and NK Cells with strong anti-tumor activity and safe profile for both immune checkpoint sensitive and insensitive PD-L1 positive tumors.
    Late-breaking abstract
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • EPIM-001